Axerion Seeks New Answers in Spinal Cord Injury, Alzheimer's
By Marie Powers
Monday, January 28, 2013
Privately held Axerion Therapeutics Inc. hopes to translate two technologies exclusively licensed from Yale University into revolutionary therapeutics in a pair of indications spinal cord injury (SCI) and Alzheimer's disease (AD) that have bedeviled biotechs and big pharmas, alike.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.